Idorsia (OTCMKTS:IDRSF) Shares Down 0.2% – Time to Sell?

Posted by Brian Himes on Sep 5th, 2026

Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) dropped 0.2% during mid-day trading on Thursday . The company traded as low as $6.24 and last traded at $6.24. Approximately 400 shares traded hands during trading, a decline of 96% from the average daily volume of 10,816 shares. The stock had previously closed at $6.25.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Idorsia in a report on Monday, August 3rd. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Check Out Our Latest Analysis on Idorsia

Idorsia Stock Performance

The company has a 50 day moving average of $7.48 and a 200-day moving average of $5.86.

About Idorsia

(Get Free Report)

Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.

Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.